Les thérapies géniques peuvent-elles devenir abordables ?

Jordan, Bertrand

doi:10.1051/medsci/2025017

dc.contributor.author	Jordan, Bertrand	-
dc.date.accessioned	2026-01-20T16:58:16Z
dc.date.available	2026-01-20T16:58:16Z
dc.date.issued	2025
dc.identifier.citation	Jordan, Bertrand ; Les thérapies géniques peuvent-elles devenir abordables ?, Med Sci (Paris), Vol. 41, N° 2 ; p. 187-189 ; DOI : 10.1051/medsci/2025017
dc.identifier.issn	1958-5381
dc.identifier.uri	http://hdl.handle.net/10608/15316
dc.description.abstract	Twenty gene therapies have now been approved in the USA by the FDA, but their stratospheric price tag (often above one million USD per patient) makes them essentially unaffordable for most. A systematic study of the various steps involved in the development and manufacture of these therapies, undertaken (among others) by the Innovative Genomics Institute in California, shows that the cost could be reduced up to tenfold without major legislative changes, and offers hope for affordable genetic therapies.	en
dc.language.iso	fr
dc.publisher	EDP Sciences
dc.relation.ispartof	Forum
dc.rights	Article en libre accès - License CC BY 4.0	fr
dc.rights	Médecine/Sciences - Inserm - SRMS	fr
dc.rights.uri	http://creativecommons.org/licenses/by/4.0
dc.source	M/S. Médecine sciences [ISSN papier : 0767-0974 ; ISSN numérique : 1958-5381], Vol. 41, N° 2; p. 187-189
dc.subject.mesh	Humains	fr
dc.subject.mesh	Californie	fr
dc.subject.mesh	Thérapie génétique	fr
dc.subject.mesh	économie	fr
dc.subject.mesh	États-Unis	fr
dc.subject.mesh	Food and Drug Administration (USA)	fr
dc.title	Les thérapies géniques peuvent-elles devenir abordables ?	fr
dc.title.alternative	Affordable gene therapies?	en
dc.type	Article
dc.contributor.affiliation	Biologiste, généticien et immunologiste, Président d’Aprogène (Association pour la promotion de la Génomique) , 13007 Marseille , France
dc.identifier.doi	10.1051/medsci/2025017
dc.identifier.pmid	40028959